普洛药业
(000739)
| 流通市值：277.92亿 | | | 总市值：278.03亿 |
| 流通股本：11.58亿 | | | 总股本：11.58亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 4,823,307,257.79 | 2,447,410,940.29 | 9,783,600,915.27 | 7,763,882,133.27 |
| 营业收入 | 4,823,307,257.79 | 2,447,410,940.29 | 9,783,600,915.27 | 7,763,882,133.27 |
| 二、营业总成本 | 4,195,088,094.34 | 2,132,762,351.94 | 8,789,064,728.76 | 6,996,741,278.28 |
| 营业成本 | 3,398,154,505.45 | 1,730,224,463.13 | 7,204,943,429.04 | 5,821,188,101.99 |
| 税金及附加 | 33,363,086.18 | 17,995,565.74 | 60,294,181.21 | 43,578,080.32 |
| 销售费用 | 223,810,088.47 | 121,604,854.55 | 548,368,269.34 | 382,944,355.1 |
| 管理费用 | 199,016,511.35 | 97,514,121.78 | 423,047,841.14 | 312,968,154 |
| 研发费用 | 278,807,433.23 | 134,928,699.35 | 611,166,878.99 | 465,006,684.23 |
| 财务费用 | 61,936,469.66 | 30,494,647.39 | -58,755,870.96 | -28,944,097.36 |
| 其中:利息费用 | 15,929,537.34 | 7,951,138.84 | 23,770,956.73 | 16,593,234.64 |
| 其中:利息收入 | 20,055,165.78 | 10,662,189.95 | 111,996,587.55 | 51,303,110.61 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 7,637,055.28 | -531,249 | - | 15,003.9 |
| 加:投资收益 | 7,890,026.96 | -1,349,205.41 | 19,780,911.88 | 33,819,960.74 |
| 汇兑收益 | - | - | - | 0 |
| 资产处置收益 | 136,291.96 | 36,622.43 | 9,032,000.65 | 1,459,491.19 |
| 资产减值损失(新) | -24,384,909.19 | -13,020,427.3 | -95,921,117.23 | -39,227,687.24 |
| 信用减值损失(新) | -24,103,116.59 | -13,243,380.09 | 12,489,926.97 | 17,709,674 |
| 其他收益 | 26,353,170.15 | 10,736,055.98 | 130,945,651.48 | 61,738,518.58 |
| 四、营业利润 | 621,747,682.02 | 297,277,004.96 | 1,070,863,560.26 | 842,655,816.16 |
| 加:营业外收入 | 1,147,626.64 | 900,742.8 | 2,949,916.27 | 1,848,698.35 |
| 减:营业外支出 | 1,276,908.27 | 363,759.82 | 7,614,607.55 | 5,364,967.73 |
| 五、利润总额 | 621,618,400.39 | 297,813,987.94 | 1,066,198,868.98 | 839,139,546.78 |
| 减:所得税费用 | 99,054,953.27 | 48,537,248.44 | 175,517,167.05 | 138,950,536.87 |
| 六、净利润 | 522,563,447.12 | 249,276,739.5 | 890,681,701.93 | 700,189,009.91 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 522,563,447.12 | 249,276,739.5 | 890,681,701.93 | 700,189,009.91 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 522,374,662.52 | 249,020,393.37 | 890,677,997.16 | 700,266,086.74 |
| 少数股东损益 | 188,784.6 | 256,346.13 | 3,704.77 | -77,076.83 |
| 扣除非经常损益后的净利润 | 495,122,577 | 242,985,574.93 | 769,277,165.57 | 647,105,200.69 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.45 | 0.22 | 0.77 | 0.61 |
| (二)稀释每股收益 | 0.45 | 0.22 | 0.77 | 0.61 |
| 八、其他综合收益 | 3,120,832.77 | 1,503,555.52 | 300,145.47 | 937,413.11 |
| 归属于母公司股东的其他综合收益 | 3,120,832.77 | 1,503,555.52 | 300,145.47 | 937,413.11 |
| 九、综合收益总额 | 525,684,279.89 | 250,780,295.02 | 890,981,847.4 | 701,126,423.02 |
| 归属于母公司股东的综合收益总额 | 525,495,495.29 | 250,523,948.89 | 890,978,142.63 | 701,203,499.85 |
| 归属于少数股东的综合收益总额 | 188,784.6 | 256,346.13 | 3,704.77 | -77,076.83 |
| 公告日期 | 2026-08-20 | 2026-04-21 | 2026-03-20 | 2025-10-22 |
| 审计意见(境内) | | | 标准无保留意见 | |